Trials / Sponsors / Shanghai Escugen Biotechnology Co., Ltd
Shanghai Escugen Biotechnology Co., Ltd
Industry · 6 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Pr Primary Sjögren Syndrome | Phase 2 | 2026-03-01 |
| Withdrawn | A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies B-cell Lymphoid Malignancies | Phase 1 | 2025-12-01 |
| Recruiting | Study of ESG406 in Adults With Solid Tumors Locally Advanced/Metastatic Solid Tumors | Phase 1 | 2025-06-04 |
| Recruiting | A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | 2025-05-08 |
| Completed | A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies B-cell Lymphoid Malignancies | Phase 1 | 2023-08-02 |
| Completed | Study of ESG401 in Adults With Solid Tumors Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal | Phase 1 / Phase 2 | 2021-09-14 |